The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with ...

This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

An unhealthy gut might be fuelling deadly nerve attacks. Here are diet tips to reduce the risk of Guillain-Barré Syndrome ...

Annexon, Inc. (NASDAQ:ANNX) on Tuesday presented data for its late-stage targeted therapy, tanruprubart (formerly ANX005), ...

To beef up its case for tanruprubart, Annexon also announced on Wednesday that a real-world study of the drug likewise showed a “rapid increase in muscle strength” versus current standards of care in ...